CN102171247A - TNF-α拮抗剂多靶点结合蛋白 - Google Patents

TNF-α拮抗剂多靶点结合蛋白 Download PDF

Info

Publication number
CN102171247A
CN102171247A CN2009801338489A CN200980133848A CN102171247A CN 102171247 A CN102171247 A CN 102171247A CN 2009801338489 A CN2009801338489 A CN 2009801338489A CN 200980133848 A CN200980133848 A CN 200980133848A CN 102171247 A CN102171247 A CN 102171247A
Authority
CN
China
Prior art keywords
conjunction
seq
territory
structural domain
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801338489A
Other languages
English (en)
Chinese (zh)
Inventor
A·K·露奎斯特
K·M·默勒
P·R·包姆
P·A·汤普森
L·米舍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trubion Pharmaceuticals Inc
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of CN102171247A publication Critical patent/CN102171247A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
CN2009801338489A 2008-07-02 2009-07-02 TNF-α拮抗剂多靶点结合蛋白 Pending CN102171247A (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US13409708P 2008-07-02 2008-07-02
US13409508P 2008-07-02 2008-07-02
US13410108P 2008-07-02 2008-07-02
US13410008P 2008-07-02 2008-07-02
US13409908P 2008-07-02 2008-07-02
US13409608P 2008-07-02 2008-07-02
US13409808P 2008-07-02 2008-07-02
US61/134,095 2008-07-02
US61/134,098 2008-07-02
US61/134,099 2008-07-02
US61/134,100 2008-07-02
US61/134,101 2008-07-02
US61/134,096 2008-07-02
US61/134,097 2008-07-02
US18009709P 2009-05-20 2009-05-20
US61/180,097 2009-05-20
PCT/US2009/049603 WO2010003108A2 (en) 2008-07-02 2009-07-02 TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS

Publications (1)

Publication Number Publication Date
CN102171247A true CN102171247A (zh) 2011-08-31

Family

ID=41051379

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801338489A Pending CN102171247A (zh) 2008-07-02 2009-07-02 TNF-α拮抗剂多靶点结合蛋白

Country Status (13)

Country Link
US (1) US20110152173A1 (https=)
EP (1) EP2310410A2 (https=)
JP (1) JP2011526792A (https=)
KR (1) KR20110044991A (https=)
CN (1) CN102171247A (https=)
AU (1) AU2009266863A1 (https=)
BR (1) BRPI0914005A2 (https=)
CA (1) CA2729749A1 (https=)
EA (1) EA201170028A1 (https=)
IL (1) IL210264A0 (https=)
MX (1) MX2011000041A (https=)
NZ (1) NZ590668A (https=)
WO (1) WO2010003108A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103060274A (zh) * 2012-12-28 2013-04-24 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用
CN104066845A (zh) * 2011-12-15 2014-09-24 皇家学术促进会/麦吉尔大学 可溶性IGF受体Fc融合蛋白和其用途
CN112451670A (zh) * 2020-11-25 2021-03-09 沣潮医药科技（上海）有限公司 异位内膜治疗的组合物和预后检测试剂盒
WO2022188883A1 (zh) * 2021-03-12 2022-09-15 上海赛金生物医药有限公司 Tnfr2与april/baff受体的融合蛋白

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
MX2011000071A (es) * 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
CA2729961C (en) * 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
AU2009303318B2 (en) * 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics
WO2011079308A2 (en) * 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
KR101004363B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제
KR101004362B1 (ko) 2010-03-19 2010-12-28 가톨릭대학교 산학협력단 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제
KR101712874B1 (ko) * 2010-09-30 2017-03-07 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 인간화 항 TNF α 항체 및 그의 항원 결합 단편 (Fab) 및 용도
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
WO2013065343A1 (ja) * 2011-10-31 2013-05-10 株式会社 島津製作所 非ペプチドヒンジ部含有フレキシブル抗体様分子
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
JP6509724B2 (ja) 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
EP2938634A2 (en) * 2012-12-28 2015-11-04 AbbVie Inc. Dual specific binding proteins having a receptor sequence
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
SG11201802698XA (en) * 2015-10-29 2018-05-30 Hoffmann La Roche Transgenic rabbit with common light chain
EP3293293A1 (en) * 2016-09-08 2018-03-14 Italfarmaco SpA Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
EP3655439A1 (en) 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019241216A1 (en) 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
CA3102641A1 (en) * 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン，エルエルシー Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）クランピング因子Ａ（ＣｌｆＡ）に対する抗体
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
US20220242962A1 (en) 2019-08-12 2022-08-04 Aptevo Research And Development Llc 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021146328A1 (en) 2020-01-13 2021-07-22 Aptevo Research And Development Llc Formulations for protein therapeutics
KR20230118573A (ko) * 2020-11-11 2023-08-11 에이치큐 한 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
WO2023164898A1 (zh) * 2022-03-03 2023-09-07 上海赛金生物医药有限公司 一种重组融合蛋白的制剂
US20250197475A1 (en) * 2022-03-18 2025-06-19 Fab Biopharma, Inc. Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
DK0695189T3 (da) * 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
US20050147609A1 (en) * 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1401870A4 (en) * 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DE10148217C1 (de) * 2001-09-28 2003-04-24 Bosch Gmbh Robert Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
WO2004011611A2 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
TW200607523A (en) * 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
EP1799246A4 (en) * 2004-10-12 2009-08-12 Amprotein Corp CHIMERIC PROTEIN
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US7939490B2 (en) * 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
PT2343320T (pt) * 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
RU2447085C2 (ru) * 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7846439B2 (en) * 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
MX2011000071A (es) * 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
CA2732574A1 (en) * 2008-07-28 2010-02-04 Philip Tan Multi-specific binding proteins targeting b cell disorders
NO2344540T3 (https=) * 2008-10-02 2018-04-28
AU2009303318B2 (en) * 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066845A (zh) * 2011-12-15 2014-09-24 皇家学术促进会/麦吉尔大学 可溶性IGF受体Fc融合蛋白和其用途
CN103060274A (zh) * 2012-12-28 2013-04-24 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用
CN103060274B (zh) * 2012-12-28 2013-12-11 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用
CN112451670A (zh) * 2020-11-25 2021-03-09 沣潮医药科技（上海）有限公司 异位内膜治疗的组合物和预后检测试剂盒
CN112451670B (zh) * 2020-11-25 2024-01-02 沣潮医药科技（上海）有限公司 异位内膜治疗的组合物和预后检测试剂盒
WO2022188883A1 (zh) * 2021-03-12 2022-09-15 上海赛金生物医药有限公司 Tnfr2与april/baff受体的融合蛋白

Also Published As

Publication number Publication date
US20110152173A1 (en) 2011-06-23
WO2010003108A2 (en) 2010-01-07
WO2010003108A3 (en) 2010-02-25
EP2310410A2 (en) 2011-04-20
CA2729749A1 (en) 2010-01-07
JP2011526792A (ja) 2011-10-20
IL210264A0 (en) 2011-03-31
BRPI0914005A2 (pt) 2015-11-17
EA201170028A1 (ru) 2011-12-30
KR20110044991A (ko) 2011-05-03
MX2011000041A (es) 2011-05-23
AU2009266863A1 (en) 2010-01-07
NZ590668A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
CN102171247A (zh) TNF-α拮抗剂多靶点结合蛋白
US20110177070A1 (en) TGF-Beta Antagonist Multi-Target Binding Proteins
US8632774B2 (en) Antagonists of IL-6
JP7263007B2 (ja) 抗ｔｌ１ａ／抗ｔｎｆ－アルファ二重特異性抗原結合タンパク質及びその使用
CN100447244C (zh) Baff受体(bcma),一种免疫调节剂
US20130052195A1 (en) Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
JP5524441B2 (ja) 短縮されたｂａｆｆレセプター
JP2015506372A (ja) ＩｇＧ２ヒンジドメインを含む融合タンパク質
WO2022055641A2 (en) Compositions and methods related to receptor pairings
US11667704B2 (en) Anti-IL-17 antibody/TNFR ECD fusion protein and use thereof
JP2008515970A (ja) キメラタンパク質
HK1161267A (en) TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS
WO2025209465A1 (zh) Taci/bcma嵌合体融合蛋白及其用途
CN101371923B (zh) Baff受体(bcma),一种免疫调节剂
WO2024123890A1 (en) Methods of using light-based chimeric proteins
HK1160175A (en) Tgf-b antagonist multi-target binding proteins
HK1162962A (en) Il6 immunotherapeutics
HK1163129A (en) Cd86 antagonist multi-target binding proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161267

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110831

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1161267

Country of ref document: HK